DOP70 An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's disease

Bram Verstockt(Universitair Ziekenhuis Leuven), Marc Ferrante(Universitair Ziekenhuis Leuven), P Sudahakar(Quadram Institute), W-J Wollants(KU Leuven), Sophie Organe(KU Leuven), Christine Breynaert(KU Leuven), Matthew Madgwick(Quadram Institute), Gert Van Assche(KU Leuven), Jonathan Cremer(KU Leuven), Brecht Creyns(KU Leuven), Tamás Korcsmáros(Eötvös Loránd University), Sare Verstockt(KU Leuven), Séverine Vermeire(KU Leuven)
Journal of Crohn s and Colitis
January 25, 2019
10.1093/ecco-jcc/jjy222.104
Cited by 12

Related Papers

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k